Asian private investors, including Hong Kong family offices, are increasingly focusing on advanced medical technologies such as brain-computer interfaces and surgical robots. With the booming biotechnology sector in China, healthcare transaction activity in Asia is accelerating. William Chow, Deputy Group CEO of Raffles Family Office, stated that Asia's aging population is driving a structural long-term demand for better surgical procedures and medications.